figshare
Browse
13063_2024_7952_MOESM1_ESM.pdf (700.04 kB)

Additional file 1 of HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial

Download (700.04 kB)
journal contribution
posted on 2024-02-15, 04:40 authored by Thomas Bais, Esther Meijer, Bart J. Kramers, Priya Vart, Marc Vervloet, Mahdi Salih, Bert Bammens, Nathalie Demoulin, Polina Todorova, Roman-Ulrich Müller, Jan Halbritter, Alexander Paliege, Emilie Cornec-Le Gall, Bertrand Knebelmann, Roser Torra, Albert C. M. Ong, Fiona E. Karet Frankl, Ron T. Gansevoort
Additional file 1.

Funding

ZonMW Otsuka Pharmaceutical

History

Usage metrics

    Trials

    Categories

    Keywords

    randomized clinical trialhighest tolerated doseh urine volumeh urinary volumeavailable creatinine valuesavailable renoprotective agentsroutine clinical careprimary study outcomepreliminary clinical studyrapidly progressive adpkdlife questionnaire scoreskidney function declineincrease renoprotective efficacydemonstrate whether comatching placebo treatmenthydrochlorothiazide versus placebohct versus placebotolvaptan decreased 24renoprotective efficacykidney functionstandard caretolvaptan efficacystudy protocolprotect studytherapeutic potentialterm effectstable treatmentrandomly assignedlike tolvaptan73 m2156 weeks

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC